

NYRx Brand Less Than Generic Program Update

What Pharmacy Providers and Prescribers Need to Know

Effective **March 20, 2025**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Ritalin LA®** and **Zegerid® Rx** will be **REMOVED** from the program **as they have been discontinued by the manufacturer**.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require "Dispense as Written" (DAW) or "Brand Medically Necessary" on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of "1"; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code "1" and "Brand Medically Necessary" on the prescription.

For a complete list, see [NYRx BLTG Program Brand Name Drugs](#) on the next page.

NYRx BLTG Drugs

| NYRx BLTG Program Brand Name Drugs* | | |
|-------------------------------------|----------------------|-----------------------|
| Advair Diskus® | Farxiga® | Risperdal Consta® |
| Advair HFA® | Forteo® | Sandostatin LAR® |
| Alphagan P® 0.15% | Glumetza® | Spiriva® HandiHaler® |
| Alphagan P® 0.1% | Istalol® | Sprycel® |
| Apriso® | Kitabis® Pak | Symbicort® |
| Azopt™ | Myrbetriq® | Tegretol® suspension |
| Bethkis® | Nexavar® | Tegretol® XR |
| Carbaglu® | NuvaRing® | Trileptal® suspension |
| Cellcept® suspension | Onglyza® | Ventolin® HFA |
| Combigan® | Oseni® | Victoza® |
| Copaxone® 20mg SQ | Pentasa® | Votrient® |
| Daytrana® | Pradaxa® | Vyvanse® capsule |
| Depakote® Sprinkle | Protonix® suspension | Xigduo® XR |
| Dymista® | Pylera® | Xopenex HFA® |
| Epipen | Restasis® | Zavesca® |
| Epipen, JR | Retin-A® cream | |

* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).
 * Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.